Insert Therapeutics

As a result, it will be up to the new court to rule on CSHL's allegations that the law firm Ropes & Gray mishandled certain RNAi-related intellectual property stemming from the work of Greg Hannon and maintained improper business relationships with RNAi drug developers.

The new allegations are an attempt by CSHL to delay a ruling on the dismissal of the lawsuit so that it can review certain RNAi companies' confidential materials, the law firm alleged.

CSHL specifically names Arrowhead Research subsidiaries Calando Pharmaceuticals and Insert Therapeutics, which were merged into one firm under the Calando name in 2008, and RXi Pharmaceuticals.

During a conference call held this week to discuss Arrowhead Research's fiscal first-quarter financial results, President and CEO Christopher Anzalone said that the company was in a position to stay afloat for at least the next nine months.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.